sq-11725 has been researched along with sotalol in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (30.43) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 7 (30.43) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; el Tayar, N; Testa, B; Van de Waterbeemd, H | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Baker, JG | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Avdeef, A; Tam, KY | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Allavena, A; Brambilla, G; Gazzaniga, GM; Martelli, A; Mazzei, M; Robbiano, L | 1 |
| Allely, MC; Ungar, A | 1 |
| Fishbein, L; Jackson, CD | 1 |
| Alexopoulos, D; Cobbe, SM; Manley, BS; Robinson, GJ | 1 |
| Lucchesi, BR; Patterson, E | 1 |
| Abed, J; Donaldson, R; Nashat, F; Taggart, P | 1 |
| Diamond, TH; Faitelson, HL; Myburgh, DP; Smith, R; Sommers, DK | 1 |
| Belli, G; Brambilla, A; Capponi, G; De Simone, L; Favilli, S; Giovannini, M; Porcedda, G; Remaschi, G; Vannuccini, F | 1 |
| Ballotari, M; Gottardo, R; Tagliaro, F; Taus, F; Utzeri, C | 1 |
2 review(s) available for sq-11725 and sotalol
| Article | Year |
|---|---|
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Models, Molecular; Receptors, Adrenergic, beta; Structure-Activity Relationship | 1988 |
A toxicological review of beta-adrenergic blockers.
Topics: Acebutolol; Adrenergic beta-Antagonists; Alprenolol; Animals; Atenolol; Cocarcinogenesis; Ethanolamines; Female; Kinetics; Labetalol; Lethal Dose 50; Male; Metoprolol; Mice; Mutagens; Nadolol; Neoplasms, Experimental; Oxprenolol; Pindolol; Practolol; Propanolamines; Propranolol; Rats; Sotalol; Timolol | 1986 |
1 trial(s) available for sq-11725 and sotalol
| Article | Year |
|---|---|
A comparison of the efficacy of sotalol and nadolol in the suppression of ventricular ectopic beats.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Humans; Middle Aged; Nadolol; Propanolamines; Pulse; Sotalol; Time Factors | 1983 |
20 other study(ies) available for sq-11725 and sotalol
| Article | Year |
|---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Algorithms; Animals; Cell Line; CHO Cells; Cricetinae; Dioxoles; Humans; Propanolamines; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Receptors, Adrenergic, beta-3 | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Formation of the N-nitroso derivatives of six beta-adrenergic-blocking agents and their genotoxic effects in rat and human hepatocytes.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Cell Survival; DNA; DNA Damage; DNA Repair; Humans; Liver; Male; Metoprolol; Nadolol; Nitrosamines; Nitrosation; Oxprenolol; Propranolol; Rats; Rats, Inbred Strains; Sodium Nitrite; Sotalol | 1991 |
Interactions of beta-adrenoceptor antagonists and thyroid hormones in the control of heart rate in the dog.
Topics: Adrenergic beta-Antagonists; Animals; Carbimazole; Dogs; Drug Interactions; Electrocardiography; Heart Conduction System; Heart Rate; Isoproterenol; Male; Nadolol; Propanolamines; Propranolol; Sotalol; Thyroid Hormones; Triiodothyronine | 1985 |
Subsidiary class III effects of beta blockers? A comparison of atenolol, metoprolol, nadolol, oxprenolol and sotalol.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Atenolol; Dose-Response Relationship, Drug; Isomerism; Metoprolol; Muscle Contraction; Nadolol; Oxprenolol; Papillary Muscles; Rabbits; Refractory Period, Electrophysiological; Sotalol | 1986 |
Antifibrillatory properties of the beta-adrenergic receptor antagonists, nadolol, sotalol, atenolol and propranolol, in the anesthetized dog.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atenolol; Dogs; Dose-Response Relationship, Drug; Heart Conduction System; Male; Nadolol; Propanolamines; Propranolol; Sotalol; Ventricular Fibrillation | 1984 |
Class III action of beta-blocking agents.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Atenolol; Cardiac Pacing, Artificial; Dogs; Electrocardiography; Female; Heart; Heart Ventricles; Male; Nadolol; Oxprenolol; Pindolol; Propanolamines; Propranolol; Sotalol; Timolol | 1984 |
Supraventricular tachycardias in the first year of life: what is the best pharmacological treatment? 24 years of experience in a single centre.
Topics: Action Potentials; Adrenergic beta-Antagonists; Age Factors; Anti-Arrhythmia Agents; Digoxin; Drug Therapy, Combination; Female; Flecainide; Heart Rate; Humans; Infant; Infant, Newborn; Male; Nadolol; Recurrence; Retrospective Studies; Sotalol; Tachycardia, Supraventricular; Time Factors; Treatment Outcome; Voltage-Gated Sodium Channel Blockers | 2021 |
Hair analysis for beta-blockers and calcium-channel blockers by using liquid chromatography-tandem mass spectrometry as a tool for monitoring adherence to antihypertensive therapy.
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Bisoprolol; Calcium; Calcium Channel Blockers; Chromatography, Liquid; Hair Analysis; Humans; Labetalol; Metoprolol; Nadolol; Nebivolol; Reproducibility of Results; Sotalol; Tandem Mass Spectrometry | 2022 |